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Abstract
 
Tumor necrosis factor (TNF) and Fas ligand (FasL) play major roles in the homeostasis of the
peripheral immune system. This becomes dramatically obvious in the absence of a functional
FasL. Mice with such a deficiency develop a profound lymphadenopathy, splenomegaly, hyper-
gammaglobulinemia, and strain-dependent systemic autoimmune disease, and succumb to pre-
mature death. It is consequently termed generalized lymphoproliferative disorder (
 
gld
 
). By con-
trast, TNF deficiency alone does not result in a striking phenotype. Thus, we sought to determine
what role TNF might play in contributing to the 
 
gld 
 
phenotype by creating C57BL/6.
 
gld
 
.TNF
 
2
 
/
 
2
 
mice. Contrary to the expected outcome, mice deficient for both FasL and TNF had a substan-
tially milder 
 
gld
 
 phenotype with regard to mortality, lymphoaccumulation, germinal center for-
mation, and hypergammaglobulinemia. To confirm these data in a strain highly permissive for
the phenotype, C3H/HeJ.
 
gld
 
 and C3H.HeJ.
 
lpr
 
 mice were treated with a TNF-specific mono-
clonal antibody. This transient neutralization of TNF also resulted in a significantly attenuated
lymphoproliferative phenotype. We conclude that TNF is necessary for the full manifestation
of the lymphoproliferative disorder, in particular playing a critical role in lymphoaccumulation.
Most importantly, absence of TNF protects 
 
gld
 
 mice against premature death.
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Introduction
 
Fas ligand (FasL),
 
 
 
a member of the TNF family, and its re-
ceptor Fas, a member of the corresponding TNF receptor
(TNFR) family, are essential in the homeostasis of the pe-
ripheral immune system (1–4). FasL is expressed predomi-
nantly on activated lymphocytes and is able to induce pro-
grammed cell death on virtually all Fas-expressing cells, if
they are receptive for its signal (2, 3). The importance of
this interaction for maintenance of lymphocyte homeostasis
has been demonstrated in vivo in the dramatic phenotype
of the disorders of generalized lymphoproliferative disorder
(
 
gld
 
)
 
1
 
 and lymphoproliferation (
 
lpr
 
) mice, two natural loss-
of-function mutations of FasL and Fas, respectively (5, 6).
In 
 
gld
 
 mice, a point mutation in the COOH-terminal region
of FasL results in the expression of a nonfunctional form of
FasL on the cell surface (7, 8). Mice homozygous for 
 
lpr
 
 and
 
gld
 
 develop remarkably similar progressive nonmalignant
lymphoproliferative diseases characterized by splenomegaly,
severe lymphadenopathy, hypergammaglobulinemia, circu-
lating autoantibodies, and premature death (5, 9–11). Lym-
phadenopathy results largely from the progressive accumu-
lation of a population of thymus-derived CD45 (B220
 
1
 
),
TCR-
 
a/b
 
1
 
, CD4
 
2
 
CD8
 
2
 
 double negative (DN) T lympho-
cytes in spleen and LNs (5).
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Abbreviations used in this paper:
 
 ABTS, 2.2
 
9
 
-azino-bis(3-ethylbenz-thiazo-
line-6-sulfonic acid); B6, C57BL/6; C3H, C3H/HeJ; DN, double negative;
ds, double-stranded; GC, germinal center; 
 
gld
 
, generalized lymphoprolifera-
tive disorder; HRP, horseradish peroxidase; 
 
lpr
 
, lymphoproliferation; mLN,
mesenteric LN; pLN, peripheral LN; TPBS, Tween/PBS; WT, wild-type. 
90
 
The Complete 
 
gld
 
 Phenotype Requires TNF
 
TNF, the prototype member of this family, is also poten-
tially important in the induction of programmed cell death
(1). This cytokine, a product of many cell types but particu-
larly of leukocytes (4, 12), not only has emerged as a media-
tor in the early stages of the inflammatory response, but also
has been demonstrated to be of importance during the effec-
tor phase mediating cell death (1). However, TNF and its re-
ceptors, TNFR-1 and -2, have been deleted by homologous
recombination, and the mouse lines so generated are normal
with respect to size and composition of their lymphocyte
compartments (13–17). The major phenotypic impact TNF
and TNFR-1 mutations have in the unchallenged mouse is
an absence of B cell follicles and a defect in the formation of
germinal centers (GCs [16, 17]) that can be attributed to de-
fects in induction of lymphocyte-homing chemokines (18).
When Fas and TNFR-1 mutations were combined by
crossing TNFR-1–deficient mice onto the 
 
lpr 
 
background,
an earlier onset and significant acceleration of the 
 
lpr
 
 pathol-
ogy were observed (19). These results seemed to indicate
that the TNF–TNFR-1 signaling pathway played some role
in peripheral homeostasis, and in particular was compensa-
tory in the absence of FasL–Fas interactions. To dissect these
interactions further, we crossed C57BL/6 (B6).TNF
 
2
 
/
 
2 
 
mice
(17) with B6.
 
gld
 
 mice (10) to generate a strain deficient for
both ligands.
In contrast to the Fas/TNFR-1–deficient mice, the ab-
sence of TNF in FasL-inactive mice protected against lym-
phoaccumulation and, coincidently, premature death, which
are characteristic of the 
 
gld
 
 mutation. The critical need for
TNF in the development of the lymphoproliferative disor-
der was further confirmed by antibody-mediated blockade
of TNF that significantly ameliorated lymphoaccumulation
and hypergammaglobulinemia in C3H/HeJ (C3H).
 
gld
 
 and
C3H.
 
lpr
 
 mice.
 
Materials and Methods
 
Mice.
 
Inbred B6 wild-type (B6.WT), C3H.
 
gld
 
, and C3H.
 
lpr
 
mice were purchased from The Walter and Eliza Hall Institute of
Medical Research. B6.
 
gld
 
 (FasL mutant; breeding colonies ob-
tained from The Jackson Laboratory), B6.TNF
 
2
 
/
 
2
 
, and B6.
 
gld
 
 
 
3
 
TNF
 
2
 
/
 
2
 
 (B6.
 
gld
 
.TNF
 
2
 
/
 
2
 
) mice were obtained from the Cente-
nary Institute of Cancer Medicine and Cell Biology, and were bred
at the Austin Research Institute Biological Research Laboratories
and the Institut für Klinische Mikrobiologie. B6.
 
gld
 
.TNF
 
2
 
/
 
2
 
 mice
were established by crossing B6.
 
gld
 
 and B6.TNF
 
2
 
/
 
2
 
 mice and sub-
sequently interbreeding the F
 
1
 
 generation. The correct double
mutant genotype was checked by PCR specific for the TNF de-
ficiency (17) and the FasL point mutation (20). All B6 genotypes
were bred on a genetically pure background. Mice of 4–48 wk of
age were used in all experiments, which were performed according
to Animal Experimental Ethics Committee guidelines of the Aus-
tin Research Institute and the University of Erlangen-Nürnberg.
 
TNF Blockade.
 
To neutralize TNF in vivo, 3-wk-old C3H.
 
gld
 
or C3H.
 
lpr
 
 mice were treated intraperitoneally every second day
with 100 
 
m
 
g of anti-TNF mAb per mouse (XT3, rat IgG
 
1
 
; provided
by Dr. Geeta Chaudri, Department of Pathology, University of Syd-
ney, Sydney, Australia) or control mAb (R3.34, rat IgG
 
1
 
; PharMin-
gen) until the mice were 14 wk of age.
 
Organ Weights and Serum ELISAs.
 
Mice were weighed and
then killed at the ages indicated. Sera were tested by ELISA for
IgG, anti–double-stranded (ds)DNA, and anti-IgG autoantibody
levels as follows. (a) IgG: ELISA plates (Costar) were precoated
with 10 
 
m
 
g/ml goat anti–mouse IgG (Sigma Chemical Co.) in
PBS for 1 h at room temperature. After seven washes in 0.05%
Tween/PBS (TPBS), plates were blocked with 2% BSA/PBS for
1 h at room temperature. Subsequent steps with intervening washes
included adding sera for 1 h at room temperature, horseradish
peroxidase (HRP)-conjugated goat anti–mouse Ig (PharMingen)
for 1 h at room temperature, and development with 2.2
 
9
 
-azino-
bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS) for 10–20
min (read at OD 405 nm). (b) Anti-dsDNA: ELISA plates (Maxi-
Sorp; Nalge Nunc International) were precoated with 10 
 
m
 
g/ml
methylated BSA in carbonate buffer overnight at 4
 
8
 
C. After four
washes in 0.05% TPBS, 10 
 
m
 
g/ml herring sperm DNA was
added in carbonate buffer overnight at 4
 
8
 
C. Plates were washed
and blocked with 2% polyethylene glycol (PEG) 8,000/1% ge-
latine/1% BSA in TPBS for 30 min at 37
 
8
 
C. Subsequent steps
with intervening washes included adding sera for 2 h at 37
 
8
 
C,
HRP-conjugated goat anti–mouse Ig for 1 h at 37
 
8
 
C, and devel-
opment with ABTS for 10–20 min (read at OD 405 nm). The
level of anti-dsDNA antibodies of B6.
 
gld
 
 at 28 wk of age was set
at 100%, and the results of the other genotypes were recorded in
relation to this level. (c) Anti-IgG: ELISA plates (MaxiSorp;
Nalge Nunc International) were precoated with 10 
 
m
 
g/ml puri-
fied rabbit IgG (Sigma Chemical Co.) in carbonate buffer over-
night at 4
 
8
 
C. After 4 washes in TPBS, plates were blocked with
1% BSA/PBS for 1 h at room temperature. Subsequent steps with
intervening washes included adding sera for 1 h at room temper-
ature, adding biotin-conjugated rat anti–mouse IgM (R6-60.2;
PharMingen) for 1 h at room temperature, adding streptavidin-HRP
for 1 h at room temperature, and development with ABTS for 30
min (read at OD 405 nm). For all ELISA assays, results were re-
corded as the mean 
 
6 
 
SE of four to six B6.WT, B6.
 
gld
 
, B6.TNF
 
2
 
/
 
2
 
,
and B6.
 
gld
 
.TNF
 
2
 
/
 
2
 
, or six or seven C3H.
 
gld 
 
or C3H.
 
lpr 
 
mice.
Organs were excised and weighed wet as follows: spleen, kid-
neys (two), mesenteric LNs (mLNs; two randomly chosen), and
peripheral LNs (pLNs; two axillary, two cervical, and two in-
guinal). Organ weights of six mice of each genotype were used
per time point. Additionally, to evaluate the anti-TNF mAb treat-
ment, the two largest C3H.
 
gld 
 
and C3H.
 
lpr
 
 pLNs were selected,
and lymphocytes were counted and the sum was totalled. These
results were recorded as the mean 
 
6 
 
SE of four to six mice. Statis-
tical significance was determined using the Student’s 
 
t
 
 test.
 
Immunofluorescence.
 
Fluorescence immunohistology was per-
formed on frozen sections. Spleen specimens were embedded in
Tissue-Tek™ OCT compound (Sakura) and snap-frozen in the
gas phase of liquid nitrogen. 6-
 
m
 
m sections were cut from tissue
blocks and thaw mounted onto glass slides. Sections were air
dried for 1 h, fixed in acetone for 30 min, and stored at 
 
2
 
20
 
8
 
C.
Before staining, sections were rehydrated with Tris-buffered sa-
line (TBS), pH 7.6, and blocked with 20% horse serum. Slides
were incubated with each antibody layer for 30–45 min at 37
 
8
 
C
in a humidified chamber, then washed with three changes of TBS
(5 min) before addition of the next layer. Primary antibodies used
were anti-B220 (purified or biotinylated; RA3-6B2), anti-CD4
(clone H129.19), and anti-CD8
 
a
 
 (clone 53-6.7), all from
PharMingen, and biotinylated peanut agglutinin (PNA; Vector
Laboratories). The staining was developed with anti–rat FITC,
anti–rat Alexa™ 594, and streptavidin-Alexa™ 594 (all from
Molecular Probes). After the final wash, slides were mounted and
examined under a Leica confocal fluorescence microscope. 
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Flow Cytometry.
 
For multiparameter analysis of splenic and
blood lymphocytes, cells were stained with anti–TCR-
 
b
 
–PE
(H57-597), anti-B220–FITC (RA3-6B2), anti-CD4–FITC (clone
H129.19), and anti-CD8
 
a
 
–PE (clone 53-6.7; all from PharMingen),
or anti-CD8
 
a
 
–Quantum red (clone 53-6.7; Sigma Chemical Co.).
In Heidelberg and Erlangen, analysis was performed on a FACSCali-
bur™ (Becton Dickinson). Statistical significance was determined
using the Student’s 
 
t
 
 test.
 
Results and Discussion
 
Attenuation of the gld Phenotype in B6.gld.TNF
 
2
 
/
 
2
 
 Mice.
 
All B6.WT and B6 gene-deficient mice were observed for
at least 420 d to assess the relative level of mortality of each
strain. B6.TNF
 
2
 
/
 
2
 
 mice (2.8% dead,
 
 n 
 
5 36) did not ex-
hibit mortality over and above that observed in B6.WT mice
(2.2% dead, n 5 45). B6.gld mice developed symptoms of
lymphoaccumulation in secondary lymphoid organs within
16–20 wk of age, and mortality was 31.9% (n 5 47) within
the first 60 wk of age.This is in agreement with the 33%
mortality within the first 12 mo described for B6.lpr mice
(11). By contrast, B6.gld.TNF2/2 mice did not show obvi-
ous signs of generalized lymphoproliferation, and mortality
levels were similar to B6.WT mice (4.1%, n 5 49). To fur-
ther analyze this observation, body weights and organ
weights of mutant mice were monitored over the first 28
wk of life. The weight of the secondary lymphoid organs
(mLNs, pLNs, and spleen) of B6.gld mice increased dramat-
ically after 16 wk of age (Fig. 1, A–C). The lymphoid organs
of B6.gld.TNF2/2 mice did increase to a minor extent after
16 wk of age. However, they were never dramatically en-
larged like the lymphoid organs in B6.gld mice (Fig. 1, A–C).
Even in much older B6.gld.TNF2/2 mice (.40 wk), the in-
crease in secondary lymphoid organ weights never reached
that observed in B6.gld mice (data not shown). Total body
weights and the weights of the kidneys increased slightly
over the 28 wk of observation, irrespective of the mouse
genotype (data not shown).
Hypergammaglobulinemia and circulating autoantibodies
are features of the gld phenotype (5). Sera from all strains of
mice at various ages were tested for IgG and autoantibodies
specific for dsDNA and IgG. B6.gld mice had higher levels of
IgG than B6.gld.TNF2/2 mice after 16 wk of age (Fig. 2 A).
Comparisons of serum IgG levels over weeks 16–28 revealed
concentrations of serum IgG (Fig. 2 A) in B6.gld.TNF2/2
mice that were z20–65% less than that of B6.gld mice. Nev-
ertheless, sera IgG levels were still elevated 10–20-fold in
B6.gld.TNF2/2 mice compared with B6.WT or B6.TNF2/2
mice. B6.TNF2/2 mice did not show Ig production higher
than B6.WT mice, as described previously (16, 17).
Extensive analysis of the lpr mutation on different genetic
backgrounds has demonstrated that this mutation results in
the formation of various autoimmune specificities (5, 11). To
study the effect of TNF deficiency on autoantibody pro-
duction, we analyzed the level of anti-IgG (rheumatoid
factor) and anti-dsDNA antibodies as representatives of
autoimmune antibodies (10). There was considerable varia-
tion in the level of anti-IgG autoantibody (IgM) detected
in various B6.gld.TNF2/2 and B6.gld mice; therefore, indi-
vidual mice were compared with the mean level of anti-IgG
in 28-wk-old B6.gld mice (normalized to 1 U). Both groups
of 24- and 28-wk-old B6.gld.TNF2/2 and B6.gld mice con-
tained some mice with at least 10–100-fold higher levels
than observed in B6.TNF2/2 or B6.WT mice (Fig. 2 B).
We additionally examined the relative levels of circulating
autoantibodies specific for dsDNA. No significant reduc-
tion in the relative levels of circulating autoantibodies spe-
cific for dsDNA was noted in B6.gld.TNF2/2 mice compared
with B6.gld mice, with both 24- and 28-wk-old B6.gld.
TNF2/2 and B6.gld mice displaying at least 10-fold higher
levels than B6.TNF2/2 or B6.WT mice (data not shown).
Taken together, it would appear that TNF plays a minor
role in hypergammaglobulinemia associated with gld, but
that neither IgG nor autoantibody levels correlated well with
Figure 1. Mice doubly mutant for FasL and TNF have significantly re-
duced lymphoaccumulation. Organs were excised from individual
B6.WT, B6.TNF2/2, B6.gld, and B6.gld.TNF2/2 mice, and wet weight
(in milligrams) was determined for (A) mLNs, (B) pLNs, and (C) spleen.
At each time point, organ weights of six B6.WT, B6.TNF2/2, B6.gld,
and B6.gld.TNF2/2 mice were determined. Total body weights ranged
from 16 to 36 g over the 4–28-wk period, regardless of the genotype.
Combined kidney weights ranged from 250 to 550 mg over the 4–28-wk
period, regardless of the genotype. Results were recorded as the mean 6
SE of six mice. Asterisks indicate the groups of B6.gld mice that are signif-
icantly different from B6.gld.TNF2/2 mice (*P , 0.04).92 The Complete gld Phenotype Requires TNF
mortality rates in these strains of mice. It remains to be deter-
mined whether a qualitative, rather than quantitative, differ-
ence exists between autoantibodies in B6.gld.TNF2/2 and
B6.gld mice. Moreover, for the manifestation of drastic
clinical symptoms that include lethal glomerulonephritis,
additional genetic requirements seem to be necessary (11).
Analysis of Composition and Localization of Lymphocyte Pop-
ulations. The gld phenotype is characterized by peripheral
accumulation of B2201 DN T cells. A flow cytometric
analysis of B6.gld peripheral lymphocytes at different ages
demonstrated an increase in the proportion of this popula-
tion in the spleens of mice .20 wk of age (21). At the same
time, the spleens of B6.gld.TNF2/2 mice contained a com-
parable proportion of B2201 DN T cells (data not shown).
Not surprisingly, the absolute number of B2201 DN T
cells was lower in the spleens of B6.gld.TNF2/2 mice,
given the smaller size of these organs. In the blood, the re-
sults were different. At 12 wk of age, B6.gld.TNF2/2 and
B6.gld mice exhibited a substantially lower number of T
cells, but no significant increase in B2201 DN T cells (Ta-
ble I). At 18–22 wk of age, B6.gld mice exhibited a signifi-
cantly higher percentage of B2201 DN T cells (11.3 6 7%,
n 5 8; Table I) than the B6.gld.TNF2/2 mice (4.1 6 2.4%,
n 5 9, P , 0.01; Table I). B6.TNF2/2 and B6.WT mice
did not accumulate these abnormal lymphocytes (Table I).
This indicates a significant retardation of the peripheral in-
crease of B2201 DN T cells in the B6.gld.TNF2/2 geno-
type. The ratio of CD41 T cells to CD81 T cells in the pe-
ripheral pool was tested in parallel in the four genotypes,
and was found to be comparable throughout and indepen-
dent of the age of the mice (data not shown).
Histological analysis of the spleen demonstrated a clear dif-
ference in the microarchitectural structure between B6.WT
and B6.TNF2/2 mice (Fig. 3, A and B), as described previ-
ously (16, 17). TNF deficiency abolished the capacity of
naive B cells to form organized follicles (compare Fig. 3, A
and B). The compartmentalization of B and T cell areas
was maintained, albeit with a relaxed demarcation between
the populations (Fig. 3 B). In 12-wk-old B6.gld mice, fol-
licle formation was clearly identifiable (Fig. 3 D). The
B6.gld.TNF2/2 strain displayed a combination of these struc-
Figure 2. Mice doubly mutant for FasL and TNF have reduced serum
IgG levels. Serum IgG (A) and anti-IgG (IgM, B) levels were determined
by ELISA from B6.WT (j), B6.TNF2/2  (s), B6.gld ( m), and
B6.gld.TNF2/2 (n) mice. Results were recorded as the mean 6 SE of (A)
four to six mice or (B) four to nine mice. In A, asterisks indicate the
groups of B6.gld mice that are significantly different from B6.gld.TNF2/2
mice (*P , 0.05). For B, 1 U was defined as the mean 6 SE of B6.gld
mice (n 5 9) at 28 wk of age. Each mouse in B is represented by an indi-
vidual symbol.
Table I. Proportional Changes in Lymphocyte Populations in the Blood of 12- and 18–22-wk-old B6.WT, B6.gld, B6.TNF2/2,
and B6.gld.TNF2/2 Mice
Age of mice
12 wk 18–22 wk
T cells B2201 DN T cells B cells T cells B2201 DN T cells B cells
B6.WT* 16 6 2.6 0.7 6 0.2 75 6 1.3 ND ND ND
B6.TNF2/2‡ ND ND ND 12.7 6 4 0.8 6 0.2 78.5 6 6
B6.gld§ 5 6 2.2 2 6 0.7 87 6 1.7 16 6 15 11.3 6 7 63 6 23
B6.gld.TNF2/2i 6 6 2.2 2.1 6 2 88 6 3.8 5.1 6 2 4.1 6 2.4¶ 1 6 5
Peripheral blood lymphocytes were stained with anti–TCR-a/b and anti-B220. Data are recorded as mean percent 6 SD.
*n 5 4.
‡n 5 4.
§n 5 5 (,12 wk of age) and 8 (18–22 wk of age).
in 5 5 (,12 wk of age) and 9 (18–22 wk of age).
¶The level of B2201 DN T cells in B6.gld.TNF2/2 mice is significantly different from that in B6.gld (P , 0.01) mice.93 Körner et al.
Figure 3. The loss of B cell follicles because of
the TNF deficiency is dominant in the doubly mu-
tant mice. This outcome does not change with age.
T and B cell localization was investigated in the
spleens of young (12 wk of age; A, B, D, and F)
and old mice (44–48 wk of age; C, E, and G). The
four genotypes were compared: (A) B6.WT; (B and
C) B6.TNF2/2; (D and E) B6.gld; and (F and G)
B6.gld.TNF2/2. T cell areas were stained in green
(FITC), and B cell areas in red (Alexa™ 594).
Original magnifications: 3200.94 The Complete gld Phenotype Requires TNF
tural phenotypes, with separated T cell compartment and
small rim-like structures of naive B cells (Fig. 3 F). The
structures that were histologically visible were composed of
naive, normal lymphocytes. At an older age (.40 wk), de-
fined splenic structures in B6.gld mice diminished (Fig. 3 E),
whereas demarcated but small and rim-like B cell areas
were still observed in B6.gld.TNF2/2 mice (Fig. 3 G).
The spleens of B6.gld mice at 12 wk of age displayed a
strong GC reaction, as determined by staining with peanut
agglutinin (Fig. 4 B). Naive B6.gld mice exhibited between
10 and 12 GCs per spleen section at the appropriate loca-
tion in the B cell follicle (Fig. 4 B). B6.WT mice of the
same age, and kept under the same conditions, displayed a
maximum of two GCs per section (Fig. 4 A). A feature of
TNF deficiency is the absence of the GC reaction (16, 17).
TNFR-1 signaling is responsible for this phenotype (22, 23).
Interestingly, this aspect of the TNF deletion was dominant
in B6.gld.TNF2/2 mice (Fig. 4 C) compared with B6.gld
mice. Nevertheless, the lack of GCs in B6.gld.TNF2/2 mice
did not compromise their ability to produce high levels of
sera Ig and autoantibodies, and this is consistent with our
analysis of Ig production in challenged B6.TNF2/2 mice,
which was also not significantly diminished (17).
Short-Term Anti-TNF mAb Treatment Reduces the gld Pheno-
type. The severity of the gld phenotype is less in the
B6.WT strain than in the highly susceptible C3H strain
(11). To examine the effect of TNF deletion in another ex-
perimental setting, we treated C3H.gld and C3H.lpr mice
with a neutralizing anti-TNF mAb or control mAb from
age 3 to 14 wk. In concert with data from B6.gld.TNF2/2
versus B6.gld mice, the serum IgG levels of C3H.gld and
C3H.lpr mice treated with anti-TNF mAb were reduced at
14 wk of age, compared with untreated or control mAb–
treated C3H.gld (P , 0.05) and C3H.lpr mice, respectively
(Fig. 5 A). More evidently, continuous anti-TNF mAb
treatment severely restricted lymphoaccumulation in the
pLNs of C3H.gld and C3H.lpr mice, with pLN weights
,30% of that observed in untreated or control mAb–treated
mice (Fig. 5 B). Moreover, pLN cell numbers were signifi-
cantly reduced (Fig. 5 C). Again, body and kidney weights
of controls were comparable in all groups of mice (data not
shown). Although anti-TNF mAb did not reduce lym-
phoaccumulation in gld mice to the same degree as gene
targeting of TNF, it must be appreciated that treatment did
not commence until mice were 3 wk of age, and that the
gld phenotype is more permissive on the C3H than on the
B6.WT background. These data support those obtained in
B6.gld.TNF2/2 mice, indicating that TNF is not necessary
to sustain all features of the gld phenotype.
Concluding Remarks. These experiments demonstrate
that the complete gld phenotype is dependent on the pres-
ence of TNF. When TNF was inhibited by antibody or
deleted by gene targeting, the TNF signaling pathway was
abrogated, and the gld phenotype was retarded in its onset
and attenuated in its severity. In particular, the lymphoac-
cumulation characteristic of the gld and lpr phenotype was
shown to be substantially dependent on TNF. In contrast,
combination of the lpr phenotype and TNFR-1 deficiency
led to an acceleration of lymphadenopathy and increased
serum Ig production (19). This contrasting outcome was
interpreted in the context of the loss of two pathways driv-
ing T cell apoptosis, thus concluding that TNF–TNFR-1
interactions normally compensate in part for the loss of the
Fas–FasL signaling pathway. An alternative view offered by
this study is that TNF actively drives lpr by signaling
through TNFR-2, and in the absence of TNFR-1 and
Fas–FasL signaling there is no mechanism to regulate this
effect. This conclusion is supported by earlier studies sug-
gesting that TNFR-2 transmits signals important for the
proliferation of thymocytes and cytotoxic T cells (24). The
dramatic increase in the severity of the lpr.TNFR-1 mutant
phenotype compared with lpr alone could be explained by
the absence of the biologically important buffer capacity of
shedded, soluble TNFR-1. Indeed, recent work has dem-
onstrated the importance of this soluble receptor in domi-
nantly inherited autoinflammatory syndromes (25). Thus, one
might also predict very high serum TNF levels in the Fas–
TNFR-1 double-deficient mice, particularly as the lack of
FasL alone leads to high levels of resting serum TNF (Wil-
helm, P., and H. Körner, unpublished results).
Figure 4.  The gld phenotype exhibits a strong GC reaction that is abolished by TNF disruption. Spleens of young mice were analyzed (12 wk of age).
B6.WT (A), B6.gld (B), and B6.gld.TNF2/2 (C) mice were compared. The B cell area was stained in green (FITC) and the GC in red (Alexa™ 594). Be-
cause of the strong green fluorescence, the overlaying red GCs appear to be yellow. Original magnifications: 3200.95 Körner et al.
It remains unclear how TNF signaling amplifies some as-
pects of the gld phenotype, particularly premature death. As
the rapid accumulation of all lymphocyte subpopulations
and, predominantly, B2201 DN T cells is due to defective
Fas-mediated apoptosis, the presence of TNF could act an-
tagonistically and inhibit the apoptotic process. Indeed, an-
tiapoptotic action of TNF on T cells has been described in
different models (26, 27). Thereafter, TNF-driven lym-
phoaccumulation and, subsequently, either plasmacytoid tu-
mors or interstitial pneumonitis would further exacerbate the
phenotype (28, 29). Finally, Fas-mediated apoptosis could
be dependent on the homing of cells to appropriate sites, and
TNF is known to promote trafficking of lymphocytes to or
within lymphoid tissues via induction of chemokines (18, 30).
In this case, the accumulation of lymphocytes in lymphoid
organs is a secondary event supported indirectly by TNF.
Without TNF, this notable feature of the gld phenotype
fails. The possibility that TNF acts as an antiapoptotic cyto-
kine in some circumstances is in contrast to a study by
Zheng et al. (31) that showed apoptotic actions of TNF via
TNFR-2 in vivo. This study postulated that TNF–TNFR-2
interactions function in the maintenance of T cell homeo-
stasis. However, it is possible that B2201 DN T cells re-
spond differently to long-lasting TNF stimulation, and their
susceptibility to TNF-mediated apoptosis is not yet known.
The issues will be addressed in future experiments.
Several treatments have been reported to decrease lym-
phoproliferative disease and to reduce the numbers of B2201
DN T cells in LNs and spleen. These include neonatal
thymectomy, chronic treatment with mAb specific for CD4,
CD8, B220, or TCR Vb, or chronic administration of cy-
closporin A or staphylococcus enterotoxin B [SEB (32–36)].
(32–36). Nevertheless, our study is the first to describe a spe-
cific molecule that contributes to lymphoaccumulation and
premature death associated with the gld phenotype. This
work demonstrates a new role of TNF, and advances our
understanding of the components leading to gld and the
mechanisms that drive manifestation of the gld phenotype.
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